title: Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
abstract: BACKGROUND
  It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis.
  
  
  METHODS
  We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC.
  
  
  RESULTS
  BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult1.15; 95% CI 0.84-1.57) and OCSS (HRmult1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult1.99; 95% CI 1.21-3.31).
  
  
  CONCLUSIONS
  Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.
authors.affiliation: Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.|Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Leendert H
authors.initials: LH
authors.lastname: Zaaijer
authors.affiliation: Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Helena C
authors.initials: HC
authors.lastname: van Doorn
authors.affiliation: Department of Obstetrics and Gynaecology, Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: Marian J E
authors.initials: MJ
authors.lastname: Mourits
authors.affiliation: Department of Obstetrics and Gynaecology, Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands.
authors.forename: Marc
authors.initials: M
authors.lastname: van Beurden
authors.affiliation: Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Joanne A
authors.initials: JA
authors.lastname: de Hullu
authors.affiliation: Department of Clinical Genetics, VU Medical Centre, Amsterdam, The Netherlands.
authors.forename: Muriel A
authors.initials: MA
authors.lastname: Adank
authors.affiliation: Center for Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: Luc R C W
authors.initials: LR
authors.lastname: van Lonkhuijzen
authors.affiliation: Foundation for the Detection of Hereditary Tumours (STOET), Leiden, The Netherlands.
authors.forename: Hans F A
authors.initials: HF
authors.lastname: Vasen
authors.affiliation: Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
authors.forename: Brigitte F M
authors.initials: BF
authors.lastname: Slangen
authors.affiliation: Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: Katja N
authors.initials: KN
authors.lastname: Gaarenstroom
authors.affiliation: Department Gynaecological Oncology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands.
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Zweemer
authors.affiliation: Department of Obstetrics and Gynaecology, Bravis Hospital, Bergen op Zoom, The Netherlands.
authors.forename: Peggy M L H
authors.initials: PM
authors.lastname: Vencken
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Caroline
authors.initials: C
authors.lastname: Seynaeve
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: Mieke
authors.initials: M
authors.lastname: Kriege
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D055815:Young Adult
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human